Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.84
+0.40003.22%
Post-market: 13.020.1800+1.40%19:50 EDT
Volume:3.35M
Turnover:43.22M
Market Cap:1.80B
PE:-3.84
High:13.13
Open:12.65
Low:12.65
Close:12.44
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:0.92
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.47
PE(LYR):-3.37

Loading ...

Intellia Therapeutics price target raised to $15 from $11 at Morgan Stanley

TIPRANKS
·
Apr 28

Intellia Therapeutics price target raised to $13 from $7 at Baird

TIPRANKS
·
Apr 28

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Biogen (BIIB)

TIPRANKS
·
Apr 27

Intellia Therapeutics Shares Jump 8% Premarket After Rare Genetic Disorder Therapy Meets Main Goal in Trial

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Reuters
·
Apr 27

Intellia starts rolling FDA BLA submission for lonvo-z in hereditary angioedema

Reuters
·
Apr 27

Intellia Therapeutics Inc - Single Dose of Lonvo-Z Frees Most Patients From Attacks and Therapy for Six Months

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Inc: Preparing for a Potential U.S. Launch of Lonvo-Z in First Half of 2027

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Inc - Phase 3 Haelo Trial of Lonvo-Z Meets Primary and All Key Secondary Endpoints

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Inc - Initiates Rolling Bla Submission With FDA for Lonvo-Z

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Inc - No Serious Adverse Events Observed With Lonvo-Z in Phase 3 Trial

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (Lonvo-Z) as a One-Time Treatment for Hereditary Angioedema

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Inc - Plans Lonvo-Z Commercial Launch in First Half of 2027 IF Approved

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

GlobeNewswire
·
Apr 27

Stock Track | Intellia Therapeutics Soars 33.46% in Pre-Market on Analyst Buy Rating and Lonvo-z Phase 3 Optimism

Stock Track
·
Apr 27

Intellia Therapeutics: Buy Rating Reiterated on Lonvo-z Phase 3 HAELO Upside Potential; $29 Price Target Maintained

TIPRANKS
·
Apr 27

Intellia to report Phase 3 HAELO trial topline data for lonvo-z on April 27

Reuters
·
Apr 25

Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws

TIPRANKS
·
Apr 11

Intellia bylaws set US federal courts as exclusive forum for Securities Act claims

Reuters
·
Apr 11

Why Intellia Therapeutics (NTLA) Is Up 14.2% After FDA Lifts MAGNITUDE Trial Holds and Upgrade

Simply Wall St.
·
Apr 07